-PTI Procedures for clinical trials in India will be further streamlined and a panel of experts set up to analyse the cause of injury or death and to recommend quantum of compensation to victims, the Government today said. Replying to a Calling Attention Motion on the issue in Rajya Sabha, Health and Family Welfare Minister Ghulam Nabi Azad said the government proposed to strengthen the rules by incorporating certain new provisions soon. He...

-The Hindu The government has issued a warning letter to Programme for Appropriate Technology in Health (PATH), asking it to be careful while conducting clinical trials so as to ensure that discrepancies and violations are not repeated in future. The Indian Council of Medical Research (ICMR) had suspended the Phase-V post licensure clinical trial being conducted by PATH, an international non-governmental organisation, in Khamman (Andhra Pradesh) and Vadodara (Gujarat) for Human Papilloma...

-Greenpeace Genetically engineered (GE) food is a hot button topic in India. What happens here often sends ripples throughout the GE debate worldwide, but what happened last week is surely a major milestone. The Parliamentary Standing Committee on Agriculture, made up of members of parliament (MPs) from across party lines, tabled its latest report (http://164.100.47.134/lsscommittee/Agriculture/GM_Report.pdf) on GE food and GE crops following intense consultation with farmers, environmental groups, scientists and consumer groups. The...

-PTI Clinical drug trials in India led to the death of 1144 people in 2010 and 2011, the government today said. The number of people dying during such trials also include 1106 people whose death could be attributed to diseases like cancer, terminal illness or various unrelated causes which is also known as Serious Adverse Event (SAE) of death, Health and Family Welfare Minister Ghulam Nabi Azad told the Rajya Sabha. "The number...

-The Economic Times Drug companies paid as little as 50,000 as compensation to families of volunteers who died during clinical trials for new medicines last year, leading to sharp criticism about the paltry sums being handed out and growing clamour among health groups for more stringent guidelines on new drug trials.  According to government data accessed by a healthcare activist through an RTI query, Germany's Fresenius Kabi paid 50,000 each to the...